Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR T-Cell therapy takes on tough blood cancers in japanese trial

NCT ID NCT06253663

Ongoing Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is. Participants also receive chemotherapy drugs (cyclophosphamide and fludarabine) before the infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KTE-X19 (CAR T-cell therapy, also known as Tecartus)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with hard-to-treat mantle cell lymphoma or B-cell acute lymphoblastic leukemia.
What could go wrong
This is a small, early-phase study (25 participants) focused on Japanese adults only. CAR T-cell therapy carries risks like severe immune reactions and side effects, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia mantle cell lymphoma precursor B-cell acute lymphoblastic leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Locations

  • Chiba University Hospital

    Chiba, 260-8677, Japan

  • Hokkaido University Hospital

    Hokkaido, 060-8648,, Japan

  • Juntendo University Hospital

    Tokyo, 113-8431, Japan

  • Kyoto University Hospital

    Kyoto, 606-8507, Japan

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • Okayama University Hospital

    Okayama, 700-8558, Japan

  • Tohoku University Hospital

    Miyagi, 980-8574, Japan

  • Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

    Tokyo, 113-8677, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.